Drug Alerts & Adverse Event Reporting

Drug Alert

Xultophy 100/3.6

Xultophy 100/3.6 is a combination insulin indicated for adults with Type 2 Diabetes Mellitus. It is associated with an increased risk of acute pancreatitis and a potential risk of medullary thyroid carcinoma. Clinicians should refer to the Xultophy 100/3.6 REMS(51 KB PDF) when prescribing this medication (link).

Receive Drug Alerts

The AAFP has partnered with PDR Drug Alerts(www.pdr.net) to help you receive FDA-mandated and product-related patient safety alerts as soon as they are issued.

Features of PDR Drug Alerts include:

  • Ability to appoint a family medicine team member to manage practice alerts
  • Free for U.S.-based prescribers
  • Traditional "dear doctor letter" (DDL) sent when online alert has not been reviewed within 72 hours (weekends not included)
  • Email addresses kept secure and confidential
  • Access to 12-month alert history master file
  • No advertisements
  • Information paid for by manufacturers required by the FDA to deliver safety alerts
  • Exclusive specialty-specific service fulfilling FDA guidance for electronic delivery of drug warnings

Get PDR Drug Alerts

Receive urgent FDA-mandated and product-related patient-safety alerts from PDR Drug Alerts.

Adverse Event Reporting

Using RxEvent, U.S. physicians and other health care providers can easily and effectively report adverse drug events. This service is a collaboration of medical professional insurance carriers and governmental experts.

Features of RxEvent include:

  • Easy-to-use, standardized report form with pre-populated information
  • Minimal required questions
  • Prompt acknowledgment sent upon submission of a report

RxEvent has been established for use by U.S. health care professionals for reporting adverse events on U.S.-distributed drugs only.


U.S. health care professionals may report adverse events on U.S.-distributed drugs only.